共 332 条
[1]
Compston A(2008)Multiple sclerosis Lancet 372 1502-1517
[2]
Coles A(2001)Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis Brain 124 2169-2176
[3]
Cepok S(2006)A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899-910
[4]
Jacobsen M(2008)B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 358 676-688
[5]
Schock S(2009)The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers Eur J Neurol 16 528-536
[6]
Omer B(2008)Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab Arch Neurol 65 1596-1603
[7]
Jaekel S(2006)Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients J Neuroimmunol 180 63-70
[8]
Boddeker I(2009)Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis Ann Neurol 66 390-402
[9]
Oertel WH(2009)Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE J Mol Med (Berl) 87 273-286
[10]
Sommer N(2009)Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis Ann Neurol 65 457-469